CD133-Targeted Niche-Dependent Therapy in Cancer
Open Access
- 1 May 2014
- journal article
- review article
- Published by Elsevier in The American Journal of Pathology
- Vol. 184 (5) , 1256-1262
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cellsCancer Cell International, 2013
- Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell DifferentiationCell Reports, 2012
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growthJournal of Experimental Medicine, 2012
- CD133 Protein N-Glycosylation Processing Contributes to Cell Surface Recognition of the Primitive Cell Marker AC133 EpitopeJournal of Biological Chemistry, 2011
- Signalling pathways in vasculogenic mimicryBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell DifferentiationCancer Research, 2010
- Concerns about anti-angiogenic treatment in patients with glioblastoma multiformeBMC Cancer, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop NormallyMolecular and Cellular Biology, 2008
- Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth FactorCancer Research, 2006